SCIENTIFIC BACKGROUND

RET, SDHAF2, SDHB, SDHC, SDHD, VHL

Category:

Scientific Background

Paraganglioma/Pheochromocytoma are rare types of tumors of the adrenal glands. They are considered as a subset of Neuroendocrine tuumors (NETs) and originate from specific cells of the neuroendocrine system. About 40% of the cases are linked to hereditary syndromes, which elevate the risk of developing cancer in the future.

 

PreSENTIA hereditary Paraganglioma / Pheochromocytoma cancer panel tests for numerous germline mutations that could cause paraganglioma or pheochromocytoma cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

 

Who is this test for?

You should get tested if you meet at least one of the criteria below:

•  You have a family or personal history of a hereditary cancer syndrome associated with paraganglioma / pheochromocytoma cancers

•  You have a family member that has been diagnosed with a germline mutation associated with cancer susceptibility.

 

How many genes are tested in this panel?

6 genes

 

How many hereditary cancer syndromes are associated with this panel?

3 Hereditary cancer syndromes are associated with this panel. These are:

Hereditary Paraganglioma – Pheochromocytoma syndrome (SDHD, SDHAF2, SDHC, SDHB)

Multiple endocrine neoplasia type 1 (MEN1)

Von-Hippel Lindau syndrome (VHL)

 

Recommendations by professional bodies

It is recommended that patients with family history of pheochromocytoma or paraganglioma should consider genetic testing to identify the genetic mutations associated with inheritance (Shah et al., 2021; NCCN).

 

References and more information: 

The information above was taken by professional bodies such as ASCO

Shah MH, Goldner WS, Benson AB, Bergsland E, Blaszkowsky LS, Brock P, Chan J, Das S, Dickson PV, Fanta P, Giordano T, Halfdanarson TR, Halperin D, He J, Heaney A, Heslin MJ, Kandeel F, Kardan A, Khan SA, Kuvshinoff BW, Lieu C, Miller K, Pillarisetty VG, Reidy D, Salgado SA, Shaheen S, Soares HP, Soulen MC, Strosberg JR, Sussman CR, Trikalinos NA, Uboha NA, Vijayvergia N, Wong T, Lynn B, Hochstetler C. Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 Jul 28;19(7):839-868. doi: 10.6004/jnccn.2021.0032. PMID: 34340212.

GENES

RET, SDHAF2, SDHB, SDHC, SDHD, VHL
How to order

LATEST ARTICLES

Antimicrobial resistance (AMR) is one of the most pressing global health threats, and accurate identification and surveillance of multidrug-resistant...

Read more

Colorectal cancer remains a significant health concern globally. While genetic factors play a crucial role in its development, identifying the exact ...

Read more

A new meta-analysis links trans-kingdom gut microbiota (bacteria, eukaryotes, viruses, archaea) to immune checkpoint inhibitor (ICI) response in canc...

Read more

Reproductive health is a fundamental aspect of human well-being, affecting individuals and communities worldwide [1]. It encompasses a wide range of ...

Read more

It seems as though everyone is talking about artificial intelligence, usually referred to as AI, these days! Indeed, not only are AI tools now access...

Read more

Orphan drugs are those developed specifically for the treatment of rare diseases. Within the pharmaceutical industry, the drug development process is...

Read more

A study of 629 pregnancies with ultrasound-detected anomalies found that exome sequencing identified pathogenic variants in 14% of cases. The detecti...

Read more

Breast cancer is a type of cancer that originates in the breast cells. Genetic changes in the DNA of the healthy breast cells can lead to the formati...

Read more

Cardiovascular diseases affect the heart and blood vessels and are a leading cause of illness and death. Some are hereditary, and genetic testing can...

Read more

A recent study tracked molecular changes in 108 people over time, revealing that aging involves critical shifts around ages 44 and 60. These changes ...

Read more